Skip to Main Content

Paper Details

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Cancer Discov
695
2014
BRAF, BRAF(, BRAF(V600), MAP2K2, MAPK, MITF, RAF, RAF inhibitor resistance genes, RAF kinase, dabrafenib, formalin, metastatic melanoma, mitogen-activated protein kinase, patients, resistance gene, tumor, tumors, vemurafenib
Author NameAffiliation
Eliezer M Van AllenDana-Farber Cancer Institute, Harvard Medical School 2Department of Pathology, Massachusetts General Hospital Cancer Center, Boston 3Broad Institute of MIT and Harvard 4Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), University Hospital, West German Cancer Center, University Duisburg-Essen, Heidelberg University Hospital, Hannover Medical School, University of Wuerzburg, University of Schleswig-Holstein Hospital, Ludwig-Maximilian University, Charite Universitatsmedizin Berlin, Humboldt University, University of Mainz, Mainz 14University Medical Center, University of Tubingen, University of Washington, University Hospital Zurich, University of Athens
Eliezer M Van AllenDana-Farber Cancer Institute, Harvard Medical School 2Department of Pathology, Massachusetts General Hospital Cancer Center, Boston 3Broad Institute of MIT and Harvard 4Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), University Hospital, West German Cancer Center, University Duisburg-Essen, Heidelberg University Hospital, Hannover Medical School, University of Wuerzburg, University of Schleswig-Holstein Hospital, Ludwig-Maximilian University, Charite Universitatsmedizin Berlin, Humboldt University, University of Mainz, Mainz 14University Medical Center, University of Tubingen, University of Washington, University Hospital Zurich, University of Athens
  • 1 - 2

Datasets